Transcarent CEO Glen Tullman previously led Livongo, which was purchased by Teladoc in a 2020 agreement that valued the ...

Download our guide to the digital therapeutics landscape, key providers, and market trends. Discover how digital health solutions can enhance pharmaceutical outcomes.

Despite the still positive FCF generation and richer balance sheet, it remains to be seen when Teladoc's growth may ...

She dismissed the case with finality. The investors alleged that Teladoc and its leadership misrepresented its integration with Livongo Health Inc. as progressing well—or fully complete—in technology, ...

Growth stocks can provide high returns but are volatile and suffered in 2022, rebounding in 2023-24. They often have higher price-to-earnings ratios, focusing on companies with innovative products ...

Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Healthcare, Utilities and Basic Materials ...

Note that in 2020, Teladoc dished out $18.5 billion to buy chronic care specialist Livongo Health. This new acquisition expands Teladoc's reach in at-home preventive care and chronic health ...

Financing led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and Company and supported by existing investors LifeArc ...

Financing led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and Company and supported by existing investors LifeArc ...